scholarly journals Risk assessment for distant metastasis in differentiated thyroid cancer using molecular profiling: A matched case‐control study

Cancer ◽  
2021 ◽  
Author(s):  
Linwah Yip ◽  
William E. Gooding ◽  
Alyaksandr Nikitski ◽  
Abigail I. Wald ◽  
Sally E. Carty ◽  
...  
Keyword(s):  
Risk Assessment ◽  
Thyroid Cancer ◽  
Distant Metastasis ◽  
Differentiated Thyroid Cancer ◽  
Case Control Study ◽  
Molecular Profiling ◽  
Case Control ◽  
Matched Case ◽  
Matched Case Control Study ◽  
Control Study

Predicting distant metastatic disease in differentiated thyroid cancer: a matched case–control study

2021 ◽  
Vol 91 (4) ◽  
pp. 716-723
Author(s):  
Sukaina Jaffar ◽  
Jayani Jayasekara ◽  
Ahmad M. Aniss ◽  
Venessa H. M. Tsang ◽  
Diana L. Learoyd ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Metastatic Disease ◽  
Differentiated Thyroid Cancer ◽  
Case Control Study ◽  
Case Control ◽  
Distant Metastatic Disease ◽  
Matched Case ◽  
Matched Case Control Study ◽  
Control Study

scholarly journals Longer Time to Reach Excellent Response to Treatment in Familial Versus Sporadic Non-medullary Thyroid Cancer (NMTC): A Matched Case-Control Study

2021 ◽  
Vol 19 (2) ◽  
Author(s):  
Susan Shafiei ◽  
Mehrdokht Sadrolodabaei ◽  
Atena Aghaei ◽  
Narjess Ayati ◽  
Samira Zare Namdar ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Case Control Study ◽  
Case Control ◽  
Response To Treatment ◽  
Control Groups ◽  
Excellent Response ◽  
Significant Difference ◽  
Matched Case ◽  
Matched Case Control Study ◽  
Control Study

Background: Familial NMTCs are supposed to be more aggressive and require more frequent treatment compared to non-familial thyroid cancer. Objectives: This matched case-control study aimed to compare the response to treatment between the matched case-control groups of familial and sporadic NMTC. Methods: This is a retrospective study in patients with familial NMTC (at least one other first-degree relative involved) who were treated with surgery, followed by radio-iodine therapy (RIT) without consideration of its familial origin. Response to treatment was compared between familial NMTC and age, sex, and TNM stage-matched non-familial NMTC (control group). Response to treatment was assessed one and two years after RIT, and time to excellent response was identified. Results: Out of 2,944 NMTC patients, 81 (2.75%) patients had familial NMTC. We compared 66 patients with familial NMTC and 66 sporadic NMTC patients. There was no significant difference in first thyroglobulin, initial and accumulative iodine dose, and additional treatments (additional surgery and radiotherapy) between patients and controls. Although no significant difference was noted in one and two years’ responses to treatment between the case and control groups, familial NMTC patients required more time to achieve excellent response (26.7 ± 24.9 versus 15.9 ± 9.0 months, P = 0.01). No significant difference was noted between familial NMTC patients with two or more than two involved relatives. Conclusions: Our study showed that if patients with familial NMTCs were treated in the same way as non-familial patients, the time to excellent response would be significantly longer, even when they have only one other involved relative.

Familial Non-Medullary Thyroid Cancer: A Matched-Case Control Study

2004 ◽  
Vol 114 (12) ◽  
pp. 2182-2186 ◽  
Author(s):  
Evelyn Linda Maxwell ◽  
Francis T. Hall ◽  
Jeremy L. Freeman
Keyword(s):  
Thyroid Cancer ◽  
Medullary Thyroid Cancer ◽  
Case Control Study ◽  
Case Control ◽  
Medullary Thyroid ◽  
Matched Case ◽  
Matched Case Control Study ◽  
Control Study

scholarly journals Serum-albumin and risk of thyroid cancer: A population-based, matched case-control study,

2009 ◽  
Vol 11 (2) ◽  
Author(s):  
Eystein Glattre ◽  
A. Engeland ◽  
A. T. Høstmark ◽  
E. Jellum
Keyword(s):  
Thyroid Cancer ◽  
Serum Albumin ◽  
Case Control Study ◽  
Population Based ◽  
Case Control ◽  
Font Size ◽  
Matched Case ◽  
Matched Case Control Study ◽  
Control Study

<strong><span style="font-family: TimesNewRomanPS-BoldMT;"><font face="TimesNewRomanPS-BoldMT"><p align="left"> </p></font></span><p align="left"><span style="font-size: x-small; font-family: TimesNewRomanPS-BoldMT;"><span style="font-size: x-small; font-family: TimesNewRomanPS-BoldMT;">NORSK SAMMENDRAG</span></span></p></strong><span style="font-size: x-small; font-family: TimesNewRomanPSMT;"><span style="font-size: x-small; font-family: TimesNewRomanPSMT;"><p align="left">Flere epidemiologiske undersøkelser fra 1980- og 1990-årene har funnet en invers assosiasjon mellom salbuminnivået</p><p align="left">og sykelighet/dødelighet av kreft. I utforskningen av skjoldkjertelkreftens etiologi og patogenese</p><p align="left">ble det derfor ansett som viktig å finne og bestemme styrken av en slik sammenheng når det gjelder</p><p align="left">skjoldkjertelkreft. Derfor ble alle med tilstrekkelig mengde serum deponert i Janusbanken og som senere i</p><p align="left">perioden 1973-1994, ifølge Kreftregisterets database, hadde fått skjoldkjertelkreft, identifisert – i alt 118</p><p align="left">tilfeller. For hvert tilfelle ble det tilfeldig valgt ut tre friske kontroller med serum i Janus. Kontrollene ble</p><p align="left">matchet mot pasientene hva gjelder kjønn, alder, bostedsfylke og serums lagringstid. Etter dette sto man</p><p align="left">igjen med 114 tilfeller (78 papillære karsinomer, 19 follikulære og 17 av andre histologiske typer) og 333</p><p align="left">kontroller. Albumin i serum ble bestemt med bromkresolgrønt-metoden og fri fettsyrer ble bestemt med en</p><p align="left">enzymatisk metode. Resultatene av denne populasjonsbaserte pasient-kontroll studien ble i korthet at man</p><p align="left">etter justering for fri fettsyrer ikke fant noen sammenheng mellom s-albumin og kreftrisiko for tilfeller der</p><p align="left">serum var tatt mer enn 6,6 år før diagnose. For serum tatt mindre enn 6,6 år før diagnose var det derimot en</p><p align="left">mulig positiv assosiasjon for de papillære karsinomene og en sannsynlig positiv assosiasjon for de follikulære</p><p align="left">karsinomene. Man fant altså ingen invers assosiasjon mellom s-albumin og skjoldkjertelkreft. I en</p><p>kortfattet diskusjon omtales noen konfunderingsfaktorer som kan ha bidratt til resultatet.</p></span></span>

Sign in / Sign up

Export Citation Format

Share Document